PortfoliosLab logoPortfoliosLab logo
ADCT vs. GERN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ADCT vs. GERN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ADCT achieves a -62.61% return, which is significantly lower than GERN's -8.33% return.


ADCT

1D
-57.14%
1M
-64.89%
YTD
-62.61%
6M
-62.71%
1Y
-60.48%
3Y*
-20.22%
5Y*
-43.03%
10Y*

GERN

1D
4.31%
1M
-26.67%
YTD
-8.33%
6M
-4.72%
1Y
-21.43%
3Y*
-30.60%
5Y*
-2.74%
10Y*
-9.04%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ADCT vs. GERN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ADCT
ADC Therapeutics SA
-62.61%77.39%19.88%-56.77%-80.99%-36.89%7.96%
GERN
Geron Corporation
-8.33%-62.71%67.77%-12.81%98.36%-23.27%-9.14%

Correlation

The correlation between ADCT and GERN is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.30

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.34

Correlation (All Time)
Calculated using the full available price history since May 18, 2020

0.33

Fundamentals

Market Cap

ADCT:

$203.47M

GERN:

$809.94M

EPS

ADCT:

-$0.99

GERN:

-$0.10

PS Ratio

ADCT:

2.31

GERN:

4.12

Total Revenue (TTM)

ADCT:

$79.18M

GERN:

$196.12M

Gross Profit (TTM)

ADCT:

$71.82M

GERN:

$119.67M

EBITDA (TTM)

ADCT:

-$87.83M

GERN:

-$40.62M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ADCT vs. GERN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADCT
ADCT Risk / Return Rank: 1111
Overall Rank
ADCT Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
ADCT Sortino Ratio Rank: 1818
Sortino Ratio Rank
ADCT Omega Ratio Rank: 1515
Omega Ratio Rank
ADCT Calmar Ratio Rank: 1010
Calmar Ratio Rank
ADCT Martin Ratio Rank: 00
Martin Ratio Rank

GERN
GERN Risk / Return Rank: 2525
Overall Rank
GERN Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
GERN Sortino Ratio Rank: 2828
Sortino Ratio Rank
GERN Omega Ratio Rank: 2828
Omega Ratio Rank
GERN Calmar Ratio Rank: 2323
Calmar Ratio Rank
GERN Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ADCT vs. GERN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ADCTGERNDifference
Sharpe ratioReturn per unit of total volatility

-0.35

Sortino ratioReturn per unit of downside risk

-0.50

Omega ratioGain probability vs. loss probability

0.90

0.99

-0.09

Calmar ratioReturn relative to maximum drawdown

-0.83

-0.53

-0.30

Martin ratioReturn relative to average drawdown

-3.27

-1.05

-2.22

ADCT vs. GERN - Sharpe Ratio Comparison

The current ADCT Sharpe Ratio is -0.69, which is lower than the GERN Sharpe Ratio of -0.34. The chart below compares the historical Sharpe Ratios of ADCT and GERN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ADCTGERNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.69

-0.34

-0.35

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.43

-0.03

-0.40

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.12

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.43

-0.07

-0.36

Drawdowns

ADCT vs. GERN - Drawdown Comparison

The maximum ADCT drawdown since its inception was -99.08%, roughly equal to the maximum GERN drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for ADCT and GERN.


Loading charts...

Drawdown Indicators


ADCTGERNDifference

Max Drawdown

Largest peak-to-trough decline

-99.08%

-98.73%

-0.35%

Max Drawdown (1Y)

Largest decline over 1 year

-72.95%

-40.51%

-32.44%

Max Drawdown (3Y)

Largest decline over 3 years

-81.64%

-78.98%

-2.66%

Max Drawdown (5Y)

Largest decline over 5 years

-98.51%

-78.98%

-19.53%

Max Drawdown (10Y)

Largest decline over 10 years

-86.09%

Current Drawdown

Current decline from peak

-97.41%

-98.27%

+0.86%

Average Drawdown

Average peak-to-trough decline

-77.35%

-86.15%

+8.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.51%

20.44%

-1.93%

Volatility

ADCT vs. GERN - Volatility Comparison

ADC Therapeutics SA (ADCT) has a higher volatility of 84.91% compared to Geron Corporation (GERN) at 14.77%. This indicates that ADCT's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ADCTGERNDifference

Volatility (1M)

Calculated over the trailing 1-month period

84.91%

14.77%

+70.14%

Volatility (6M)

Calculated over the trailing 6-month period

96.84%

46.98%

+49.86%

Volatility (1Y)

Calculated over the trailing 1-year period

87.83%

63.13%

+24.70%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

99.82%

82.40%

+17.42%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

94.75%

78.07%

+16.68%

Dividends

ADCT vs. GERN - Dividend Comparison

Neither ADCT nor GERN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ADCT vs. GERN - Financials Comparison

This section allows you to compare key financial metrics between ADC Therapeutics SA and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
20.85M
51.84M
(ADCT) Total Revenue
(GERN) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ADCT and GERN have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ADCT has higher volatility (84.91%) compared to GERN (14.77%). In terms of maximum drawdown, ADCT dropped -99.08% vs GERN's -98.73%.

GERN currently has the higher Sharpe Ratio (-0.34 vs -0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ADCT and GERN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer